Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Study to Evaluate the Accuracy of Primary Care Diagnosis Using Oscillometry and Fractional Exhaled Nitric Oxide for Asthma and COPD Versus Specialist Diagnosis in Patients With Suspected Asthma or COPD

Status: Recruiting
Location: See all (12) locations...
Study Type: Observational
SUMMARY

Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a foundational tool, its diagnostic accuracy is often limited by the patient's ability to perform forceful breathing maneuvers, as well as technical and reproducibility challenges, and the need for proper equipment and training. These constraints can compromise effective diagnosis of asthma and COPD in primary care settings. Prompt and accurate diagnosis by primary care physicians is essential for better patient outcomes. Although variable airflow limitation often measured as a change in FEV1 after bronchodilator is a hallmark of asthma, inconsistencies in test quality and reversibility criteria create challenges in distinguishing asthma from COPD. These complexities highlight the need for alternative diagnostic tools beyond traditional spirometry. This observational study is designed to evaluate the diagnostic accuracy and technical feasibility of using oscillometry and FeNO testing in primary care for suspected asthma and COPD, compared to conventional specialist-based diagnostics. The study will be conducted across 6 countries in the MEA, Asia, and Latin America, with two hospital sites per country. Primary care physicians will be trained in oscillometry and FeNO testing using standardized protocols and tools such as the Ambulatory Lung Diagnosis System following GINA and GOLD guidelines. Eligible patients will provide consent, complete a history and symptom questionnaire, and undergo primary care-based assessment for a provisional diagnosis. If specialist assessment cannot occur the same day, it will be done within three days. No follow-up visits are planned. Study outcomes will inform the feasibility and accuracy of integrating these methods into routine care, aiming to improve the early and reliable diagnosis of asthma and COPD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Patients are eligible to be included in the study if all the following criteria apply and after providing written informed consent:

⁃ Suspected asthma (asthma group)

• Patients ≥ 18 years old or with legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the ICF.

• Patients presenting with symptoms of wheezing, cough, chest tightness, shortness of breath, but without a clinically confirmed diagnosis of asthma.

⁃ Suspected COPD (COPD group)

• Patients ≥ 40 years old at the time of signing the ICF.

• Patients presenting with symptoms of dyspnea, chronic cough or sputum production, but without a clinically confirmed diagnosis of COPD.

Locations
Other Locations
Argentina
Research Site
RECRUITING
Buenos Aires
Research Site
RECRUITING
Medoza
Egypt
Research Site
NOT_YET_RECRUITING
Alexandria
Research Site
NOT_YET_RECRUITING
El Waili
Mexico
Research Site
NOT_YET_RECRUITING
Monterrey
Research Site
NOT_YET_RECRUITING
Santiago De Quer Taro
Saudi Arabia
Research Site
NOT_YET_RECRUITING
Riyadh
Taiwan
Research Site
NOT_YET_RECRUITING
Taichung
Research Site
NOT_YET_RECRUITING
Taoyuan
United Arab Emirates
Research Site
NOT_YET_RECRUITING
Dubai
Viet Nam
Research Site
NOT_YET_RECRUITING
Hanoi
Research Site
NOT_YET_RECRUITING
Ho Chi Minh City
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-12-26
Estimated Completion Date: 2027-04-30
Participants
Target number of participants: 600
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov